Logo

Lilly Presents Updated Data of Verzenio (abemaciclib) in P-III monarchE Trial Presented at ESMO and Published in the Annals of Oncology

Share this
Lilly Presents Updated Data of Verzenio (abemaciclib) in P-III monarchE Trial Presented at ESMO and Published in the Annals of Oncology

Lilly Presents Updated Data of Verzenio (abemaciclib) in P-III monarchE Trial Presented at ESMO and Published in the Annals of Oncology

Shots:

  • The P-III monarchE trial assessed Verzenio (150mg- bid) + SOC vs SOC alone in patients with EBC in a ratio (1:1) for 2yrs. Patients in both treatment arms were instructed to continue to receive adjuvant ET for up to 5-10 years as recommended by their clinician
  • In the updated analysis- the benefits of IDFS and DRFS were maintained. @3yrs; absolute improvement rates in IDFS and DRFS (5.4% and 4.2%). With additional follow up- the treatment benefit was maintained over time and extended beyond the 2yrs. treatment period
  • Consistent Verzenio treatment benefit in reducing the risk of recurrence was observed in patients regardless of Ki-67 score

Click here to­ read the full press release/ article | Ref: Eli Lilly | Image: WRGB


Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Related News/Articles

We Have a Viewership of 1,00,000 + Views

Join the PharmaShot Family